Silence Therapeutics
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12 Hammersmith Grove, London, Greater Lo...Phone Number
+442034576900Website
www.silence-therapeutics.comRevenue
<$5 MillionStock Symbol
SLNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
2
1
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.Explore more
Silence Therapeutics Org Chart
CR
Chief Medical Officer & Senior VP
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Silence Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Silence Therapeutics
Check out if Silence Therapeutics is spiking on competitors!
Earning: See what the market has to say on Silence Therapeutics recently announced quarterly report
Silence Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Silence Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Silence Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Silence Therapeutics has new funding data
Check if Silence Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Silence Therapeutics
Find more new buyers
Compare Similar Companies to Silence Therapeutics
Compare insights from companies similar to Silence Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Silence Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Silence Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Silence Therapeutics.
Silence Therapeutics financials insights
Gather financial insights about Silence Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Private Equity
$20M
2026
Stock/Share Issuance
$201.3M
Silence Therapeutics Tech Stack
A closer look at the technologies used by Silence Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Project
conducted a sensitivity analysis on 40 Phase 2 patients meeting the same stringent phlebotomy-dependency criteria as Phase 1, demonstrating a response rate of nearly 90% with a very low placebo response rate, further supporting the robustness of diviserin's primary endpoint results.
Pharmaceuticals, Clinical Operations
Project
Silence Therapeutics has completed enrollment for the Sanreco Phase 2 trial, which enrolled 48 patients across 9 countries on 4 continents, including the U.S., Europe, Southeast Asia, and Australia, following a prior healthy volunteer study in 24 patients and a Phase 1 portion in 21 patients.
Medical Research, Pharmaceuticals, Clinical Operations
Project
reported that diviserin was well tolerated in the Sanreco Phase 2 trial, with no new safety signals identified, injection site reactions that were infrequent, self-limiting, and all grade 1, and only two grade 1 investigator-reported adverse events of anemia, with a modest and non-concerning elevation in platelets consistent with the drug's hepcidin-directed mechanism.
Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
Silence Therapeutics News & Media
Silence Therapeutics completes private fund raise at USD 201.3m for divesiran trial - AllSci
Silence Therapeutics closes $201.3M funding round to advance divesiran Phase III trial in polycythemia vera. Positive Phase II data supports development.Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript
Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera August 10, 2026 8:00 AM EDTCompany...The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
$SCKT is today's standout mover, while biotech names $ABCL, $SLN, $NTHI are announcing major clinical milestonesSilence Therapeutics shares surge ahead of divesiran Phase 2 results call
Silence Therapeutics (NASDAQ:SLN) shares jumped 16. 2% in pre-market trading on Monday as investors positioned ahead of a conference call covering topline results from the Phase 2 SANRECO trial of divesiran, the company’s lead siRNA candidate for polycythemia vera.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Silence Therapeutics
Sign Up For FreeTo access detailed company insights
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for poly... Read More
